statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024...

Replimune Group announces inducement grants under Nasdaq listing rule

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...

Replimune Group (REPL, $8.24) price moved above its 50-day Moving Average on March 27, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Replimune Group announces CEO transition

Replimune Group announces CEO transition...

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1...

Replimune Group (REPL, $8.11) Aroon Indicator entered an Uptrend on March 20, 2024.

Over the last three days, A.I.dvisor has detected that REPL's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Replimune Group (REPL, $8.11) price may climb as it broke lower Bollinger Band on Mar 20, 2024

This price move could be a signal that REPL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Replimune Group (REPL, $8.26) Aroon Indicator entered an Uptrend on March 19, 2024.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Volume	623,965.00
52-Wk High	$21.63
52-Wk Low	$4.92

REPL Replimune Group Inc

About

Feed

News

Sentiment

Earnings

Fundamentals